Skip Navigation


Glycobiology Advance Access originally published online on December 8, 2004
Glycobiology 2005 15(4):393-407; doi:10.1093/glycob/cwi020
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Correction to PDF
Right arrow A correction has been published
Right arrow All Versions of this Article:
15/4/393    most recent
cwi020v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jamois, F.
Right arrow Articles by Vetvicka, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jamois, F.
Right arrow Articles by Vetvicka, V.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Glycobiology vol. 15 no. 4 © Oxford University Press 2004; all rights reserved.

Glucan-like synthetic oligosaccharides: iterative synthesis of linear oligo-ß-(1,3)-glucans and immunostimulatory effects

Frank Jamois2, Vincent Ferrières3, Jean-Paul Guégan3, Jean-Claude Yvin2, Daniel Plusquellec3 and Vaclav Vetvicka1,4

2 Laboratoire Goëmar, ZAC La Madeleine, Avenue du Général Patton, 35400 Saint Malo, France; 3 Synthèses et Activations de Biomolécules, UMR CNRS 6052, Ecole Nationale Supérieure de Chimie de Rennes, Avenue du Général Leclerc, F-35700 Rennes, France; and 4 Department of Pathology, University of Louisville, 511 S. Floyd Street, MDR Building, Louisville, KY 40202


1 To whom correspondence should be addressed; e-mail: vetvickavaclav{at}netscape.net

Received on September 21, 2004; revised on November 30, 2004; accepted on December 2, 2004

Small reducing and linear oligo-ß-(1,3)-glucans, which are able to act as phytoallexin elicitors or as immunostimulating agents in anticancer therapy, were synthesized according to an iterative strategy that involved a unique key monosaccharidic donor. To avoid anomeric mixtures, the reducing entity of the target oligomers was first locked with benzyl alcohol and further selective deprotection of the 3-OH with DDQ afforded the desired building block as an acceptor. The latter was then used in a second cycle of glycosylation/deprotection to afford the desired disaccharide, and successive reiterations of this process provided the desired oligomers. Unusual conformational behaviors were observed by standard NMR sequences and supported by NOESY studies. Finally, removal of protecting groups afforded free tri-, tetra-, and pentaglucosides in good overall yields. Two oligosaccharides representing linear laminaritetraose and laminaripentaose were compared to the recently described ß-(1,3)-glucan phycarine. Following an intraperitoneal injection, the influx of monocytes and granulocytes into the blood and macrophages into the peritoneal cavity was comparable to that caused by phycarine. Similarly, both oligosaccharides stimulated phagocytic activity of granulocytes and macrophages. Using ELISA, we also demonstrated a significant stimulation of secretion of IL-1ß. Together these results suggest that the synthetic oligosaccharides have similar stimulatory effects as natural ß-(1,3)-glucans.

Key words: carbohydrates / glycosides / glycosylation / immunostimulation / oligosaccharides


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.